Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +65

Gilead Sciences stock gets new Livdelzi Phase 3 evidence

Clinical trial results Regulatory submission AI-generated analysis

πŸ“ˆ Gilead Sciences reported positive Phase 3 IDEAL results for Livdelzi in primary biliary cholangitis patients with moderately elevated ALP levels.

πŸ”¬ At Week 52, 75.4% of participants on Livdelzi achieved the composite endpoint for alkaline phosphatase normalization versus 16.1% on placebo.

πŸ“… The IDEAL study enrolled adults whose ALP levels were above normal but below 1.67 times the upper limit despite ursodeoxycholic acid treatment.

πŸ—£οΈ Gilead plans to engage global regulatory authorities based on these new clinical milestone results.

πŸ₯ The data will be presented at The Liver Meeting in Denver alongside real-world evidence for Livdelzi and Hepcludex.

πŸ’° Gilead Sciences stock traded 1.75% higher at 157.27 euros following the announcement of the positive clinical trial data.

Bullish Signals
  • Gilead Sciences achieved a 75.4% response rate for alkaline phosphatase normalization in the IDEAL Phase 3 study, significantly outperforming the 16.1% placebo rate.
  • The positive Livdelzi data expands the company's liver disease pipeline and supports future regulatory discussions with global authorities.
  • Gilead Sciences stock price increased by 1.75% to 157.27 euros on Thursday, reflecting investor reaction to the new clinical evidence.
Full Analysis
Gilead Sciences announced positive Phase 3 IDEAL study results for its drug Livdelzi in patients with primary biliary cholangitis (PBC). The trial evaluated the treatment in adults with moderately elevated alkaline phosphatase levels who had either failed ursodeoxycholic acid therapy or could not tolerate it. The data was published by Business Wire ahead of a presentation at The Liver Meeting in Denver. At Week 52 of the study, 75.4% of participants receiving Livdelzi achieved the composite endpoint for alkaline phosphatase normalization, compared to only 16.1% of those on placebo. This response was observed after one month and remained sustained through the end of the trial period. The results significantly expand the clinical evidence base for Livdelzi in this specific patient population. Following the positive data, Gilead plans to engage with global regulatory authorities to discuss potential future pathways for the drug. While this engagement does not represent an immediate approval or filing announcement, it marks a significant milestone for the company's liver disease pipeline. The stock price reflected the news, trading 1.75% higher on Thursday.